Heart failure management includes the four pillars (quad therapy) in HFrEF and HFpEF, plus advances in heart transplantation ...

Repairon’s groundbreaking regenerative heart failure therapy is being evaluated in a Phase 2 clinical study in Germany. As reported recently, an interim analysis presented at the 2025 Scientific ...

AB-1002 is administered via antegrade intracoronary artery infusion. The Food and Drug Administration (FDA) has granted Fast Track designation to AB-1002 for the treatment of congestive heart failure ...

CHICAGO — For patients with advanced heart failure, an injection of autologous mononuclear cells into damaged myocardia missed the primary endpoint in the sham-controlled, randomized, blinded CardiAMP ...

First-in-human trial of AB-1002 designed to evaluate safety and preliminary efficacy in participants with New York Heart Association (NYHA) Class III heart failure Trial enrolled 11 participants in ...

A critical review of cell-based and cell product-based therapies for the treatment of heart failure details 20 years of completed and ongoing clinical trials. While none has yet gained medical ...

Utilization of the four pillars in heart failure therapy are highlighted as aggressive first-line treatment strategies. This is a video synopsis/summary of a panel discussion involving Robert Groves, ...

Atrial fibrillation (AF) and chronic heart failure (CHF) are two major and even growing cardiovascular conditions that often coexist. However, few data are available to guide treatment of AF in ...

"We believe these encouraging early results in patients with advanced heart failure are important for the congestive heart failure community, as they bring hope to a sub-population where treatment ...

Earlier this month, the FDA approved an exciting new drug called Entresto, which is used to treat patients with congestive heart failure (CHF). CHF is a disease state in which the heart muscle becomes ...